Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Rheumatology and Therapy|December 19, 2022
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus MethotrexateRoy Fleischmann, Boulos Haraoui, Maya H Buch, et al.
The Open Rheumatology Journal|January 4, 2018
Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA StudyCarter Thorne, Gilles Boire, Andrew Chow, et al.
The Journal of Rheumatology|April 15, 2023
Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid ArthritisJeffrey R Curtis, Paul Emery, Greg Kricorian, et al.
Rheumatology (Oxford, England)|August 15, 2019
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 yearsJanet Pope, Louis Bessette, Niall Jones, et al.
Clinical Therapeutics|June 6, 2022
Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate CombinationStanley B Cohen, Boulos Haraoui, Jeffrey R Curtis, et al.
Clinical Rheumatology|August 28, 2012
Subsequent entry biologics/biosimilars: a viewpoint from CanadaAnthony S Russell, Vandana Ahluwalla, Cheryl Barnabe, et al.
Rheumatology (Oxford, England)|September 13, 2015
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritisEdward C Keystone, Janet E Pope, J Carter Thorne, et al.
Rheumatology and Therapy|April 13, 2026
Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL StudyBoulos Haraoui, Denis Choquette, Cristina Sciortino, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 18, 2020
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained RemissionJeffrey R Curtis, Paul Emery, Elaine Karis, et al.
Rheumatology and Therapy|July 20, 2024
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE StudyAndrea Rubbert-Roth, Koji Kato, Boulos Haraoui, et al.
Pageof 14